Dr Michael M Aiken, MD | |
501 W Brow Rd, Lookout Mountain, TN 37350-1115 | |
(423) 267-5003 | |
(423) 265-5680 |
Full Name | Dr Michael M Aiken |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 501 W Brow Rd, Lookout Mountain, Tennessee |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124242193 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 0000012779 (Tennessee) | Primary |
208D00000X | General Practice | 022204 (Georgia) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Dr Michael M Aiken, MD 501 W Brow Rd, Lookout Mountain, TN 37350-1115 Ph: (423) 267-5003 | Dr Michael M Aiken, MD 501 W Brow Rd, Lookout Mountain, TN 37350-1115 Ph: (423) 267-5003 |
News Archive
A lung transplant often remains the only option for many patients with end-stage lung disease, a condition that can be brought on by emphysema, pulmonary fibrosis, cystic fibrosis and other lung disorders.
Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.
Santarus, Inc., a specialty biopharmaceutical company, has expanded its development pipeline with the addition of two novel biologic drug candidates focused on specialty markets.
A researcher at Oregon Health & Science University and the Portland Veterans Affairs Medical Center is calling upon the U.S. Food and Drug Administration (FDA) to share more information provided by pharmaceutical companies regarding their clinical drug trials.
› Verified 2 days ago